Results

Total Results: 2,279 records

Showing results for "factor".

  1. effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/recombinant-factor-viia_clinician.pdf
    October 01, 2010 - Vessel Conditions Off-Label Uses of rFVIIa Key Clinical Issue Off-label use of recombinant activated factor … of bleeding in patients with hemophilia A or B with inhibitors, acquired hemophilia, or congenital factor … Utilization and Clinical Data on In-Hospital, Off-Label Uses of Recombinant Factor VIIa 1 In January … information in this guide is based on Comparative Effectiveness of In-Hospital Use of Recombinant Factor
  2. effectivehealthcare-admin.ahrq.gov/products/recombinant-factor-viia/research
    March 01, 2020 - Evidence Reports Comparative Effectiveness of In-Hospital Use of Recombinant Factor … SHARE: Comparative Effectiveness of In-Hospital Use of Recombinant Factor … currently available to support the effectiveness and safety of using recombinant activated coagulation factor … Project Timeline Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label … https://effectivehealthcare.ahrq.gov/products/recombinant-factor-viia/research  
  3. effectivehealthcare-admin.ahrq.gov/products/recombinant-factor-viia/clinician
    March 01, 2020 - Reports Utilization and Clinical Data on In-Hospital Off-Label Uses of Recombinant Factor … Utilization and Clinical Data on In-Hospital Off-Label Uses of Recombinant Factor … Key Clinical Issue Off-label use of recombinant activated factor VII (rFVIIa) in the hospital setting … of bleeding in patients with hemophilia A or B with inhibitors, acquired hemophilia, or congenital factor … https://effectivehealthcare.ahrq.gov/products/recombinant-factor-viia/clinician  
  4. effectivehealthcare-admin.ahrq.gov/products/recombinant-factor-viia/slides
    March 01, 2020 - Home Evidence Reports Effectiveness and Off-Label Use of Recombinant Factor … SHARE: Effectiveness and Off-Label Use of Recombinant Factor … Project Timeline Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label … Citation: Presentation: Effectiveness and Off-Label Use of Recombinant Factor … https://effectivehealthcare.ahrq.gov/products/recombinant-factor-viia/slides  
  5. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/hemophilia-dental-rapid-response.pdf
    July 01, 2024 - "[ot] OR "Factor IX Deficiency"[ot] OR "Christmas Disease"[ot] OR "factor viii deficiency"[ot] OR "factor … 8' OR 'antih*emophilic factor' OR 'antih*emophilic globulin' OR 'factor viii' OR 'factor ix' OR 'factor … ix' OR 'factor xi' OR 'plasma thromboplastin component' OR 'factor 8' OR 'factor 9' OR f9 OR 'factorfactor VIII by 2%. … “Antihemophilic factor is not the only answer for all factor VIII deficiencies.”
  6. Layout 1 (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_executive.pdf
    May 01, 2010 - currently available to support the effectiveness and safety of using recombinant activated coagulation factor … uses in hemophilia patients who have developed antibody inhibitors that compromise the use of standard factor … Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs … rFVIIa is a form of human factor VII produced by recombinant technology. … VIII or factor IX, respectively.
  7. effectivehealthcare-admin.ahrq.gov/health-topics/hemophilia
    July 11, 2024 - If you have hemophilia, you have little or no clotting factor. … Clotting factor is a protein needed for normal blood clotting. … The main treatment is injecting the missing clotting factor into the bloodstream.
  8. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/rfviia.pptx
    May 01, 2010 - Introduction to Recombinant Activated Factor VII (rFVIIa) Yank V, et al. … Introduction to Recombinant Activated Factor VII (rFVIIa) Recombinant activated factor VII (rFVIIa) … X activation, even in the absence of tissue factor. … Recombinant factor VIIa for warfarin-associated intracranial bleeding. … Activated recombinant factor VII in orthotopic liver transplantation.
  9. effectivehealthcare-admin.ahrq.gov/sites/default/files/rfviia.pptx
    May 01, 2010 - Introduction to Recombinant Activated Factor VII (rFVIIa) Yank V, et al. … Introduction to Recombinant Activated Factor VII (rFVIIa) Recombinant activated factor VII (rFVIIa) … X activation, even in the absence of tissue factor. … Recombinant factor VIIa for warfarin-associated intracranial bleeding. … Activated recombinant factor VII in orthotopic liver transplantation.
  10. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_disposition-comments.pdf
    June 01, 2010 - Comparative Effectiveness of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care. … Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. … Treatment of traumatic bleeding with recombinant factor VIIa. … Recombinant activated coagulation factor VII and bleeding trauma patients. … " or "Factor IX" or "Factor VIII" as if they were proper nouns, which they are not.
  11. effectivehealthcare-admin.ahrq.gov/products/musculoskeletal-complaints-tests-children/research
    December 01, 2019 - Home Evidence Reports Antinuclear Antibody, Rheumatoid Factor … SHARE: Antinuclear Antibody, Rheumatoid Factor … Structured Abstract Objectives To assess the test performance of antinuclear antibody (ANA), rheumatoid factor … Project Timeline Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for … Internet Citation: Systematic Review: Antinuclear Antibody, Rheumatoid Factor
  12. effectivehealthcare-admin.ahrq.gov/health-topics/rh-incompatibility
    Rh factor is a protein on red blood cells. Most people are Rh-positive; they have Rh factor. … Rh factor is inherited though genes. … Blood tests can tell whether you have Rh factor and whether your body has made antibodies.
  13. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/COVID-19-pharmaceutical-treatments-rapid-review.pdf
    March 01, 2024 - RR = 0.98; CI: 0.06, 15.05 Neurosensory alteration: 0/40, 1/39 RR = 0.33; CI: 0.01, 7.95 Risk factor … units Titer: high titer Timing: 9 days Control: Placebo Cutoff: 45 days or less: 28 Risk factor … Analysis Risk of Bias (ROB) RR = 2.96; CI: 0.12, 72.49 Risk factor analysis: NR Pub … Analysis Risk of Bias (ROB) RR = 3.03; CI: 0.12, 74.27 Risk factor analysis: NR Pub … Analysis Risk of Bias (ROB) RR = 3.02; CI: 0.12, 73.90 Risk factor analysis: NR Pub
  14. effectivehealthcare-admin.ahrq.gov/products/dcis-prognostic-tests/research
    December 01, 2019 - Home Evidence Reports Data Points #15: Prognostic factor … SHARE: Data Points #15: Prognostic factor … Current guidelines do not recommend routine testing for human epidermal growth factor receptor 2 (HER2 … Project Timeline Data Points #15: Prognostic factor testing among older women with ductal carcinoma … Internet Citation: Research Report: Data Points #15: Prognostic factor
  15. effectivehealthcare-admin.ahrq.gov/products/hemophilia-dental/research
    July 01, 2024 - appropriate timing for hemophilia patients to receive dental care in order to improve outcomes in response to factor … Several guidelines recommended that dental treatment be scheduled to occur in tandem with factor replacement … Dental procedures should be performed as close to the time of administration of factor concentrate as … procedures that required local anesthesia, it was recommended that children on routine prophylaxis receive factor
  16. effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/TND_0068_01-30-2009.pdf
    January 01, 2009 - Results of Topic Selection Process & Next Steps  Antinuclear autoantibody and rheumatoid factor … The nominator is interested in the diagnostic accuracy of antinuclear antibody (ANA) and rheumatoid factor … 3. a) What is the diagnostic accuracy of antinuclear antibody (ANA) and rheumatoid factor (RF) for children … vague musculoskeletal complaints  Age  Race/ethnicity Antinuclear Autoantibody and Rheumatoid Factor
  17. effectivehealthcare-admin.ahrq.gov/products/musculoskeletal-complaints-tests-children/research-protocol
    December 01, 2019 - The rheumatoid factor (RF) test is the most commonly used serological test to determine the presence … Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: A review. … Rheumatoid factor test (RF): The measure of serum level of rheumatoid factor antibody which is an antibody … exp Antibodies, Antinuclear/ ((antinuclear adj antibod*) or (antinuclear adj factor*)).ti,ab. … exp Rheumatoid Factor/ (rheumatoid adj factor*).ti,ab.
  18. effectivehealthcare-admin.ahrq.gov/products/deliberative-methods/research-2013-1
    January 01, 2019 - Evidence of physical harm was the most persuasive factor in accepting boundaries. … Evidence of economic harm was also a persuasive factor in restricting choice. … After completing a factor analysis using the attitude items, our final attitude measures included six … Ratings for the factor assessing facilitator neutrality were fairly high. … For the implementation process, CD reported higher scores for the factor implementation quality.
  19. effectivehealthcare-admin.ahrq.gov/products/infertility/research
    March 01, 2022 - syndrome (PCOS), endometriosis, unknown reasons, or tubal or peritoneal factors or (b) couples with male factor … for PCOS, 7 for endometriosis, 50 for infertility secondary to unknown causes, 8 for tubal/peritoneal factor … infertility, 23 for male factor infertility, and 5 for outcomes in male and female gamete donors. … For couples with male factor infertility, live birth rate (moderate SOE) and miscarriage (low SOE) did … Evidence concerning specific comparisons was insufficient for couples with tubal factor or endometriosis
  20. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/deliberative-methods-demonstration-executive-131125.pdf
    November 01, 2013 - • Evidence of physical harm was the most persuasive factor in accepting boundaries. … • Evidence of economic harm was also a persuasive factor in restricting choice. … Ratings for the factor assessing facilitator neutrality were fairly high. … For the quality of communication and discourse, CD reported higher scores for the factor respect for … For the implementation process, CD reported higher scores for the factor implementation quality.

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site: